Last month, the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed Read More
1500 JFK Blvd. (Two Penn Center), Suite 404
Philadelphia, PA 19102